3 December 2014

The European Haemophilia Consortium held on 19-21 November 2014 its first New Technology Workshop in Dublin, Ireland. The event brought together 40 participants from 17 countries to present the various novel technologies in haemophilia treatment that are expected to come to the European market in the next two to three years.

The workshop provided an overview at novel technologies such as pegylation, albumin fusion and FC fusion. Participants also had the opportunity to hear on further developments from the biclonal antibody for the treatment of haemophilia A. The programme also included two workshops on priotirisation on access and economic access for these treatments. Finally, participants heard about the EU regulatory landscape and how to determine the value on novel longer acting products.

Speakers included Mr Brian O’Mahony, president of the EHC; Prof Flora Peyvandi and Prof Paul Giangrande from the EHC Medical Advisory Group as well as:

  • Prof Johannes Oldenburg from the University of Bonn
  • Dr Barry White from the Irish National Haemophilia Centre
  • Dr Beatrice Nolan from Our Lady’s Children’s Hospital
  • Mr David Page from the Canadian Haemophilia Society
  • Mr Uwe Schlenkrich from the German Haemophilia Society
  • Dr Manuel Carcao from Sick Children’s Hospital in Toronto
  • Mr Declan Noone from the Irish Haemophilia Society
  • Dr Nogami from Nara University in Japan

Consult the article on the workshop in the December 2014 issue of the EHC Newsletter.